Abstract
https://www.nejm.org/doi/pdf/10.1056/NEJMc2300400
1 clinical trial
2 products
2 drugs
1 indication
1 target
Clinical trial
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's DiseaseStatus: Completed, Estimated PCD: 2022-03-24
Indication
Huntington's diseaseProduct
TominersenProduct
PlaceboDrug
tominersenDrug
placeboTarget
None